. Author manuscript; available in PMC: 2012 Oct 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):e40–e43. doi: 10.1097/QAI.0b013e31822b8bf8

Table 1.

Baseline characteristics and pharmacokinetic measurements of levonorgestrel, ethinyl estradiol, nevirapine, lamivudine and stavudine

Drug	PK	Group 1 (HIV+ ARV+) N=3	Group 2 (HIV+ ARV−) N=3	Group 3 (HIV Negative) N=3
LNG	C_0hr	6.11 [3.50–7.02]	4.72 [4.03–7.36]	1.41[1.04–4.03]
	AUC_0–8hr	78.3 [5.37–83.8]	52.4 [49.2–79.9]	24.0 [23.4–58.7]
	AUC_0–24hr	147 [112–177]	114 [105–139]	37.9 [36.9–107]
EE	C_0hr	57.3 [40.8–60.7]	82.2 [67.1–98.2]	47.0 [39.3–81.7]
	AUC_0–8hr	817 [611–820]	816 [765–1,019]	670 [664–837]
	AUC₀–_24hr	1,384 [1,130–1,425]	1,457 [1,371–1,610]	1,144 [1,111–1,583]
NVP	C_0hr	8,456 [6,542–12,229]
	AUC_0–8hr	77,791 [60,989–108,395]
	AUC_0–24hr	111,596 [86,761–149,259]
3TC	C_0hr	146 [125–137]
	AUC_0–8hr	7,393 [7,010–9,381]
	AUC_0–24hr	8,278 [7,946–10,668]
d4T	C_0hr	0
	AUC_0–8hr	1,974 [1,647–2,204]
	AUC_0–24hr	2,029 [1,889–2,273]

Data presented as Median [interquartile range]; LNG, levonorgestrel; EE, ethinyl estradiol; NVP, nevirapine; 3TC, lamivudine; d4T, stavudine. All C_0hr represented as ng/mL except EE (pg/mL). All Area Under the Curve (AUC) represented as ng*mL/hr except EE (pg*mL/hr).